PR Newswire·Dec 3, 2025, 4:15 PM ET

POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

POM

Pomdoctor Limited reported unaudited financial results for the six months ended June 30, 2025, showing a 16.2% increase in net revenue to RMB174.5 million (US$24.4 million) from RMB150.2 million in the prior period.
Net loss for the first half of 2025 was RMB19.9 million (US$2.8 million), an increase from RMB14.0 million in the same period of 2024.
Gross profit rose 16.3% to RMB28.3 million (US$4.0 million), maintaining a stable gross profit margin of 16.2%.
Online-pharmacy revenue surged 83.2% to RMB66.4 million (US$9.3 million), contributing significantly to the overall growth in Internet hospital revenues which increased 82.4% to RMB67.2 million.
Sales and marketing expenses increased 11.6% to RMB27.8 million due to higher doctor service fees and staff costs, partially offset by reduced advertising spending.
General and administrative expenses jumped 53.5% to RMB10.5 million, primarily driven by consultancy and professional service fees related to the company's initial public offering.
The company completed its IPO in October 2025, selling 5,750,004 ADSs at US$4.00 per share for gross proceeds of US$23.0 million before expenses.
Cash and cash equivalents decreased to RMB5.7 million as of June 30, 2025, compared to RMB7.7 million as of December 31, 2024.
Net cash used in operating activities was RMB15.0 million for the six months ended June 30, 2025, compared to RMB10.6 million in the prior year period.
Net loss per share (basic and diluted) was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared to RMB10.58 in the same period of 2024.
The gross profit margin for the Internet hospital business declined to 40.5% from 44.7% due to increased sales of lower-margin pharmacy products, while the pharmaceutical supply chain margin fell to 1.1% from 6.9%.